Welcome to Hepatitis Delta Connect!
A dedicated program of the Hepatitis B Foundation to increase awareness about hepatitis delta - a serious virus that coinfects hepatitis B patients - and to promote screening and testing, and provide information and support for those affected.
Clinical Trial Finder - Find A Clinical Trial Near You!
Register for Upcoming Webinar!
Hear from expert researcher and clinician, Dr. Robert J. Wong, as he discusses his paper on the significant clinical and economic burden of hepatitis delta in the United States. Register here!
New White Paper on Hepatitis Delta Research, Awareness, Screening, and Linkage to Care
The Hepatitis B Foundation took the lead on publishing a white paper about the urgent action needed to make advancements in hepatitis D research, awareness, and patient care. Read it here!
New Clinical Practice Guidelines from the European Association for the Study of the Liver (EASL)
EASL has recently published hepatitis delta clinical guidelines with recommendations for testing and surveillance. Read the new guidelines here!
Are You Interested in Participating in a Study?
Are you living with hepatitis delta virus (HDV) in the United States? Join a new research study! Researchers from the University of Miami are interested in hearing your experiences with diagnosis and treatment, to improve access to appropriate and individualized care. The study involves a one-hour virtual interview, and compensation is available!
If you are interested in participating, please complete a brief survey here!
We would love to hear from you! Complete the survey to sign up! Please note: This survey link is specifically for those living with hepatitis delta, or those who are caretakers of people living with hepatitis delta.
Take our brief survey & sign up to receive updates on clinical trials, info about hepatitis delta monitoring, management & care + more! Sign up today! Please note: This survey link is specifically for healthcare providers caring for people living with hepatitis delta.
We've educated 13,000 people in 111 countries!
News & Updates
Advances in Viral Hepatitis B and D: Moving Toward the Goals of Elimination - A book from Dr. Robert Gish, leading expert in Hepatitis Delta, is available for purchase
October 2023 Presentation: Hepatitis Delta: Increasing Awareness and Treatment Competencies For Practicing Clinicians
October 2023 Presentation: Disease Progression Among Commercially Insured Hepatitis Delta Virus Infected Patients in the United States
November 2023 Blog Post: The Provider’s Perspective on Hepatitis Delta: A Conversation with Ilan Weisberg, MD
June 2023 Blog Post: Drug Profile: Three Hepatitis Delta Therapies That We Hope to See Widely Available Soon
March 2023 Blog Post: Why Is Hepatitis Delta So Hard to Eliminate?
December 2022 Blog Post: What You Need to Know About the 2022 Liver Meeting and How it Relates to Hepatitis Delta
11/17/2023: Prevalence and characteristics of Hepatitis delta virus infection in patients with hepatitis b in the united states: An analysis of the All-Payer Claims Database
11/14/2023: Replicor updates REP 2139-Mg compassionate use and mechanistic data at AASLD 2023
11/9/2023: Hepatitis D: A Review
11/2023: Maternal-to-Child Transmission of Hepatitis B Virus and Hepatitis Delta Virus
11/2023: Hepatitis D: a neglected aspect of elimination efforts
10/25/2023: Comparative effectiveness of seven interventions for chronic hepatitis D: a systematic review and network meta-analysis of randomized controlled trials
10/03/2023: The elimination of hepatitis D as a public health problem: Needs and challenges
10/03/2023: AB-1659, A Potent Orally Bioavailable NTCP Inhibitor That Blocks Entry of HBV/HDV Viruses
10/02/2023: Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor
09/12/2023: Late-Stage Trial in Chronic Hepatitis D Discontinued Due to Safety Concerns
08/14/2023: Prevalence and genotypes distribution of virus hepatitis B and hepatitis delta virus in chronic liver diseases in Kazakhstan
08/12/2023: An Insight Into the Factors Affecting the Prevalence and Natural History of Hepatitis D
08/07/2023: A promising investigational therapeutic monoclonal antibody to treat chronic hepatitis B and D infections
07/28/2023: New Study Dismantles Everything We Knew About The Disease
07/26/2023: Diagnosis and Management of Hepatitis Delta Virus Infection
07/26/2023: Development of quantitative multiplex RT-qPCR one step assay for detection of hepatitis delta virus
07/24/2023: Prevalence and determinants of hepatitis delta virus infection among HIV/hepatitis B-coinfected adults in care in the United States
07/06/2023: A Glimmer of Hope for an Orphan Disease
07/06/2023: Hepatitis D Virus Infection
07/06/2023: A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D
06/29/2023: Lonafarnib regimens ‘exceed end-of-treatment response’; oral therapy may be viable in HDV
06/28/2023: Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022
06/24/2023: Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D
06/23/2023: Gilead reports positive results in HDV patients previously unresponsive to therapy
06/23/2023: Gilead data reinforce case for Hepcludex in hepatitis delta
06/23/2023: EASL Clinical Practice Guidelines on hepatitis delta virus
06/22/2023: Advancing research, awareness, screening, and linkage to care to eliminate HDV in the U.S.
06/21/2023: Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference
06/21/2023: Significantly Higher Clinical and Economic Burden Following Diagnosis of Hepatitis Delta Virus Infection Among Commercially Insured Adults With Chronic Hepatitis B in the United States
06/14/2023: Hepatitis Delta Virus Infection in the United States: If You Seek, You May Find
06/01/2023: Bluejay Therapeutics Advances in Hepatitis B and D Trials: Successfully Completes BJT-778 Phase 1a Study and Begins Phase 1b Trial Enrollment
05/17/2023: The Many Functions Of The Hepatitis D Antigen Proteins
05/16/2023: Hundreds of NHS patients in England and Wales offered access to first treatment conditionally licensed for the most aggressive form of viral hepatitis
05/15/2023: With NICE nod, Gilead clears another regulatory hurdle in Europe for Hepcludex
05/10/2023: RNA Gymnastics: How Does Hepatitis Delta Virus Replicate?
05/05/2023: After FDA rejection, Gilead's Hepcludex looks set for full EU nod
04/07/2023: Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression
04/06/2023: Molecular and Clinical Features of Hepatocellular Carcinoma in Patients with HBV-HDV Infection
04/06/2023: Hepatitis D double reflex testing of all hepatitis B carriers in low HBV and high HBV/high HDV prevalence countries
Get Connected
